RedHill Enrolls Last Patient in Bekinda Phase 3 Trial for Acute Gastroenteritis

RedHill Enrolls Last Patient in Bekinda Phase 3 Trial for Acute Gastroenteritis
RedHill Biopharma has enrolled the last patient in a Phase 3 clinical evaluating Bekinda (24 mg) for the treatment of acute gastroenteritis and gastritis. The drug, targeting multiple gastrointestinal indications, is also being evaluated in inflammatory bowel syndrome (IBS), according to a company press release. The randomized, double-blind, placebo-controlled Phase 3 GUARD clinical trial (NCT02246439) is evaluating

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *